首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >A Phase 3 Randomized Double-Blind Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

【2h】

A Phase 3 Randomized Double-Blind Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

机译：第3期随机双盲多中心研究评估静脉Iclaprim与万古霉素治疗怀疑或证实归因于革兰氏阳性病原体的急性细菌皮肤和皮肤结构感染的安全性和有效性（REVIVE-2研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Antimicrobial Agents and Chemotherapy
作者
Thomas L. Holland; William ORiordan; Alison McManus; Elliot Shin; Ali Borghei; Thomas M. File Jr.; Mark H. Wilcox; Antoni Torres; Matthew Dryden; Thomas Lodise; Toyoko Oguri; G. Ralph Corey; Patrick McLeroth; Rajesh Shukla; David B. Huang;
展开▼
作者单位

展开▼
年(卷),期 2018(62),5
年度 2018
页码 e02580-17
总页数 10
原文格式 PDF
正文语种
中图分类药学;微生物学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study) [J] . Holland Thomas L., ORiordan William, McManus Alison, Journal of neurosurgical sciences . 2018,第5期

机译：第3期，随机，双盲，多中心研究，以评估静脉内Iclaprim对急性细菌皮肤和皮肤结构感染的静脉内Iclaprim对急性细菌皮肤和皮肤结构感染的安全性和疗效进行刺激或证实是由于革兰氏阳性病原体（Revive-2研究）
2. A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study) [J] . Holland Thomas L., ORiordan William, McManus Alison, Antimicrobial agents and chemotherapy. . 2018,第5期

机译：第3期，随机，双盲，多中心研究，以评估静脉内Iclaprim对急性细菌皮肤和皮肤结构感染的静脉内Iclaprim对急性细菌皮肤和皮肤结构感染的安全性和疗效进行刺激或证实是由于革兰氏阳性病原体（Revive-2研究）
3. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1 [J] . Huang David B., ORiordan William, Overcash J. Scott, Clinical infectious diseases . 2018,第8期

机译：第3阶段，随机，双盲，多中心研究，评价静脉内Iclaprim与急性细菌皮肤和皮肤结构感染治疗急性细菌皮肤和皮肤结构感染的安全性和疗效，刺激或证实是由于革兰氏阳性的病原体：Revive-1
4. 1338. A Pooled Analysis of Patients With Wound Infections in the Phase 3 REVIVE Trials: Randomized Double-blind Studies to EValuate the Safety and Efficacy of Iclaprim Vs. Vancomycin for trEatment of Acute Bacterial Skin and Skin Structure Infections [O] . David Huang, G Ralph Corey, Thomas L Holland, -1

机译：1338.在3期REVIVE试验中对伤口感染患者的汇总分析：评估Iclaprim Vs的安全性和有效性的随机双盲研究。万古霉素治疗急性细菌性皮肤和皮肤结构感染
5. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim vs. Vancomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens (REVIVE-1) [O] . David Huang, Patrick Mcleroth, Rajesh Shukla, 2017

机译：3期，随机，双盲，多中心研究，以评估静脉内IClaprim与万古霉素治疗急性细菌皮肤和皮肤结构感染的安全性和功效，刺激或证实是由于革兰氏阳性病原体（Revive-1 ）

A Phase 3 Randomized Double-Blind Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

著录项

引文网络

相似文献

相关主题

期刊订阅